• Conduit expands its partnership with Sarborg to apply advanced machine learning-driven analysis on clinical data from its AstraZeneca-acquired assets, aiming to uncover new insights and optimize development pathways.
  
   

NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announces that it has entered into an additional license and use agreement (the "Additional Agreement") with Sarborg Limited ("Sarborg") to expand the scope of work on Conduit's acquired AstraZeneca assets, including AZD1656, AZD5658, and AZD5904.

Under the agreement, Sarborg will apply its proprietary machine learning algorithms to conduct an in-depth analysis of Conduit's clinical and safety data, with the goal of uncovering missed insights, identifying potential drug repurposing opportunities, and highlighting gaps in existing datasets. A key focus will be the re-evaluation of historical clinical trial data, including endpoints, to determine whether specific patient subgroups may have demonstrated therapeutic benefits, findings that could refine Conduit's future clinical development strategy.

Sarborg has granted Conduit a non-exclusive, non-transferable license to access its advanced algorithmic platform for the duration of the six-month agreement. The collaboration builds upon the existing Services Agreement between the two parties, which remains in full effect.